Armata Pharmaceuticals, Inc.

For the period ended Jun 30, 2026. Filed Aug 12, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 12, 2026

ARMP$3.75-1.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(in thousands, except share and per share data)


· Three Months Ended June 30, · · Six Months Ended June 30,
· 2026 · · 2025 · · 2026 · · 2025
Grant and award revenue	$2,510	$2,169	$3,299	$2,660
Operating expenses
Research and development	7,586	6,394	13,697	11,823
General and administrative	5,236	2,619	8,699	5,872
Total operating expenses	12,822	9,013	22,396	17,695
Operating loss	(10,312)	(6,844)	(19,097)	(15,035)
Other income (expense)
Interest income	69	108	129	167
Interest expense	(6,634)	(3,808)	(12,193)	(7,410)
Change in fair value of the Convertible Loan	91,018	(5,751)	(10,044)	(548)
Total other income (expense), net	84,453	(9,451)	(22,108)	(7,791)
Net income (loss)	$74,141	$(16,295)	$(41,205)	$(22,826)
Per share information:
Net income (loss) per share, basic	$2.02	$(0.45)	$(1.12)	$(0.63)
Weighted average shares outstanding, basic	36,747,840	36,193,479	36,639,663	36,189,165
Net loss per share, diluted	$(0.27)	$(0.45)	$(1.12)	$(0.63)
Weighted average shares outstanding, diluted	62,041,700	36,193,479	36,639,663	36,189,165

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.